Functional Connectivity Changes During Early Recovery as a Marker for Relapse

Overview

The study purpose is to examine whether there are structural or functional differences in the brains of individuals who use cocaine or amphetamines as opposed to control participants who have never used cocaine or amphetamines. More specifically, it will allow the investigator to see how the brain changes once people get sober and how those changes relate to successful recovery. This study will allow the investigator to examine the interaction between cocaine/amphetamines and impulsivity (meaning to act on impulse rather than thought). Results from this study will inform new biologically-based interventions to compliment existing treatment programs, in the hope of leading the field in a new direction.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: March 4, 2020

Interventions

  • Device: MRI: Brain Imaging Data Collection
    • This study has no intervention, it is observational. The investigator will collect brain imaging data and behavioral assessments.

Arms, Groups and Cohorts

  • Substance Use Disorder (SUD)
    • Participants in the SUD group will: Complete a diagnostic screening interview at baseline. Complete questionnaires and computer tasks at baseline, 1 month and 2 month time points. Complete MRI brain imaging data collection at the baseline, 1 month and 2 month time points. Complete 9 follow-up phone calls to assess for relapse.
  • Healthy Control (HC)
    • Participants in the HC group will: Complete a diagnostic screening interview at baseline. Complete questionnaires and computer tasks at baseline and 2 month time points. Complete MRI brain imaging data collection at the baseline and 2 month time points.

Clinical Trial Outcome Measures

Primary Measures

  • Brain connectivity
    • Time Frame: Change from Baseline, to 2 months
    • 3T MRI scan

Participating in This Clinical Trial

Inclusion Criteria

  • At least 18 but no more than 45 years old at the time of consent. – Able to provide written consent and comply with study procedures. Exclusion Criteria:

  • Any medical condition or treatment with neurological sequelae (i.e. stroke, tumor, loss of consciousness for more than 30 minutes, seizures, HIV). – Any contraindications to MRI scanning (i.e. metal implants, pacemakers, etc.). – Intellectual developmental disorder as defined in the DSM-V. Participant may have a diagnosis of an Axis I disorder (i.e. anxiety disorders, mood disorders, eating disorders, psychotic disorders), but it must be considered stable. – Actively suicidal. – Positive screen for alcohol and/or drugs. Participants who screen positive for drugs and/or alcohol may return at a later date to screen for the study again. – Evidence for Wernicke-Korsakoff syndrome. – Healthy Controls may never have had any form of substance use disorder other than caffeine or nicotine. Nicotine use will be recorded but will not be an exclusion criterion.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 45 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University of Minnesota
  • Collaborator
    • National Institute on Drug Abuse (NIDA)
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Kelvin O Lim, MD, Principal Investigator, University of Minnesota

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.